Physician profile
Trisha A Taylor
NPI 1518069731
$5,496.98
in general payments reported to CMS, 2019-2025
32 companies · $458 in 2025
The $458 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $650 · 2021: $1,035 · 2022: $575 · 2023: $986 · 2024: $653 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.85 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,561.34 | 2020-2025 | |
| Abbvie INC. | $1,393.87 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $378.98 | 2019-2024 | |
| Merz North America, INC. | $328.66 | 2019-2020 | |
| Janssen Biotech, INC. | $255.93 | 2019-2023 | Tremfya |
| Lilly USA, LLC | $177.70 | 2019-2023 | Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $166.40 | 2019-2024 | |
| Allergan, INC. | $126.79 | 2019-2022 | |
| Genzyme Corporation | $115.78 | 2019-2024 | |
| Leo Pharma INC. | $105.96 | 2019-2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $99.60 | 2020-2025 | Dupixent |
| Celgene Corporation | $86.61 | 2019 | |
| Genentech USA, INC. | $80.43 | 2019-2021 | |
| Almirall LLC | $76.68 | 2019-2021 | |
| Galderma Laboratories, L.P. | $72.22 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.17 | 2021-2025 | Otezla, Otezla |
| Dusa Pharmaceuticals, INC. | $70.89 | 2019 | |
| Aclaris Therapeutics, INC. | $50.78 | 2019 | |
| Kerecis Limited | $31.03 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Epi Health, LLC | $27.15 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.67 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $20.53 | 2019 | |
| Botanix Sb INC | $19.69 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $19.28 | 2021 | |
| Incyte Corporation | $19.12 | 2021 | |
| Organogenesis INC. | $18.28 | 2021 | |
| Astellas Pharma US INC | $16.00 | 2022 | |
| Biofrontera INC. | $15.63 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $12.05 | 2019 | |
| Ucb, INC. | $11.54 | 2021 | |
| Merck Sharp & Dohme LLC | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.